(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 17.7% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 36.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Alpha Teknova's revenue in 2026 is $39,801,000.On average, 8 Wall Street analysts forecast TKNO's revenue for 2026 to be $2,429,153,916, with the lowest TKNO revenue forecast at $2,284,089,855, and the highest TKNO revenue forecast at $2,596,700,231. On average, 5 Wall Street analysts forecast TKNO's revenue for 2027 to be $2,885,543,654, with the lowest TKNO revenue forecast at $2,628,175,385, and the highest TKNO revenue forecast at $3,085,689,235.
In 2028, TKNO is forecast to generate $3,521,416,712 in revenue, with the lowest revenue forecast at $3,383,311,443 and the highest revenue forecast at $3,624,995,663.